• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

KemPharm inks drug discovery deal with AI-driven biopharma

October 23, 2018 By Sarah Faulkner

Kempharm logo updatedKemPharm (NSDQ:KMPH) said today that it inked a collaboration with twoXar to develop prodrug-based therapies for an array of therapeutic indications.

According to the deal, twoXar’s artificial intelligence-based drug discovery technology will be used alongside KemPharm’s Ligand Activated Therapy platform to identify and develop new prodrug therapies.

In conjunction with its deal with twoXar, KemPharm also inked a research and license deal with twoXar subsidiary Novoxar to develop a prodrug that could form the basis of a target drug product candidate for Novoxar. The companies have not disclosed the therapeutic area that they are targeting with this investigational prodrug.

“Today’s announcement of a technology collaboration between twoXar and KemPharm, and the related research and license agreement with Novoxar, provide KemPharm’s team with another opportunity to apply our prodrug expertise to a potentially under-served therapeutic area, and ultimately bring potential new benefits to patients,” Travis Mickle, KemPharm’s president & CEO, said in prepared remarks. “We believe this collaboration has the potential to create long-term value for our shareholders by potentially extending KemPharm’s reach into new therapeutic areas, creating long-term patent protection and, together with twoXar, further de-risk and accelerate the product development cycle.”

“KemPharm’s LAT technology provides a path to creating unique and valuable drug candidates,” twoXar’s co-founder & CEO Andrew Radin added. “The KemPharm team’s technology and drug development experience combined with twoXar’s discovery technology enables a route to greater efficiency in drug development.”

KMPH shares were trading at $2.33 apiece in mid-morning activity today, down -4.1%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Discovery, Featured, Pharmaceuticals, Wall Street Beat Tagged With: kempharm

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS